Amgen's Denosumab Trumps Zometa with Top-Line Results for Cancer Bone Complications
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen has great expectations for denosumab, but the drug still has a long road ahead and an upcoming FDA Advisory Committee review before it hits the market.
You may also be interested in...
With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo
Despite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.
With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo
Despite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.
Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.